Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?
Allogene Therapeutics(ALLO.US) Director Sells US$26,181.12 in Common Stock
$Allogene Therapeutics(ALLO.US)$ Director Humer Franz B sold 11,200 shares of common stock on May 30, 2024 at an average price of $2.3376 for a total value of $26,181.12.Source: Announcement What is s
Express News | Allogene Therapeutics: Under Share Exchange Agreement, Jv Company Acquired From Overland 100% Equity Interest in Overland Pharmaceuticals (US) Inc
Express News | Allogene Therapeutics Inc: On May 24, Co, Overland Pharmaceuticals, Allogene Overland Biopharm Entered Into a Share Exchange Agreement
Allogene Therapeutics Initiated at Overweight by Piper Sandler
Allogene Therapeutics Initiated at Overweight by Piper Sandler
Piper Sandler Initiates Coverage On Allogene Therapeutics With Overweight Rating, Announces Price Target of $11
Piper Sandler analyst Biren Amin initiates coverage on Allogene Therapeutics (NASDAQ:ALLO) with a Overweight rating and announces Price Target of $11.
Institutional Investors May Adopt Severe Steps After Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) Latest 12% Drop Adds to a Year Losses
Key Insights Significantly high institutional ownership implies Allogene Therapeutics' stock price is sensitive to their trading actions A total of 8 investors have a majority stake in the company w
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T)
JMP Securities Maintains Allogene Therapeutics(ALLO.US) With Hold Rating
JMP Securities analyst Reni Benjamin maintains $Allogene Therapeutics(ALLO.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 35.5% and a total average return of -6.
Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of James Hardie Industries plc (NYSE:JHX) fell sharply during Tuesday's session after the company reported worse-than-expected quarterly financial results.James Hardie Industries posted adjuste
Allogene Therapeutics Shares Jump 10% on Share Purchases by Chairman, CEO
By Denny Jacob Allogene Therapeutics shares jumped 10% on Tuesday after company insiders bought up shares, often an indication of confidence by leadership. Shares were trading around $2.83. The stoc
Insider Trading: Allogene Therapeutics' Insider Buys Shares Worth $5M
ASTS, ALLO and CMCM Are Among Premarket Gainers
Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Shares of Larimar Therapeutics, Inc.. (NASDAQ:LRMR) rose sharply in today's pre-market trading after the company announced that the FDA removed the partial clinical hold previously placed on the nomla
Allogene Therapeutics Is Maintained at Outperform by Oppenheimer
Allogene Therapeutics Is Maintained at Outperform by Oppenheimer
Express News | Allogene : Oppenheimer Cuts Target Price to $13 From $14
Express News | Oppenheimer Maintains Outperform on Allogene Therapeutics, Lowers Price Target to $13
Analysts Are Bullish on These Healthcare Stocks: Savara (SVRA), Allogene Therapeutics (ALLO)
Allogene Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Allogene Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | Allogene Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $9 From $10
No Data